BioTech

Adverse events platform built for FDA approval and long-term compliance

A pre-approval biopharma company needed a REMS portal to manage adverse events at FDA scale. We built it from scratch: secure, validated, and audit-ready.

The Business Challenge

A biopharma company navigating clinical trials and approaching FDA approval needed a centralized portal within their Risk Evaluation and Mitigation Strategy. The portal had to consolidate and triage adverse events and product complaints from multiple sources.

Their existing process was manual. Manual meant error-prone. Error-prone meant compliance exposure at exactly the wrong moment in the regulatory timeline.

Our Approach

We built a responsive, multi-step submission framework that captured structured data across all devices and validated it before it ever reached the database. A centralized document collection system handled cloud storage, access controls, and secure on-demand retrieval. Automated, customized reporting replaced the manual process end to end.

Security was built into the hosting environment from day one, not layered on after the fact.

The Impact

The platform guided each adverse event from initial submission to final resolution, removing the uncontrolled handoffs that had created compliance risk. Error rates dropped. Audit readiness became a default state, not a fire drill before each regulatory review.

More case studies

Global content platform serving 12 regions and 6 languages for a payment processor

A global payment processor had marketing content scattered across disconnected systems. We consolidated everything into a single managed AEM platform with automated translation and self-service publishing.

Read more

Healthcare provider portal across five brands, built for compliance and self-service

A pharmaceutical company managing five brands needed a compliant, multi-channel content platform that put healthcare providers in control. We migrated them off a legacy CMS and rebuilt the architecture around modularity and auditability.

Read more